{
    "root": "75fb7964-98b4-46a4-9a8b-01515626d281",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Desvenlafaxine Succinate",
    "value": "20250313",
    "ingredients": [
        {
            "name": "DESVENLAFAXINE SUCCINATE",
            "code": "ZB22ENF0XR"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "desvenlafaxine extended-release tablet indicated treatment adults major depressive disorder ( mdd ) [ ( 14 ) ] .",
    "contraindications": "\u2022 recommended dose : 50 mg daily without food ( 2.1 ) . \u2022 evidence doses greater 50 mg per day confer additional benefit ( 2.1 ) . \u2022 25 mg per day dose intended gradual reduction dose discontinuing treatment dosing severe renal end-stage renal disease patients ( 2.1 ) . \u2022 discontinuation : reduce dose gradually whenever possible ( 2.1 ) . \u2022 take tablets whole ; divide , crush , chew , dissolve ( 2.1 ) . \u2022 moderate renal impairment : maximum dose 50 mg per day ( 2.2 ) . \u2022 severe renal impairment end-stage renal disease : maximum dose 25 mg per day 50 mg every day ( 2.2 ) . \u2022 moderate severe hepatic impairment : maximum dose 100 mg per day ( 2.3 ) .",
    "warningsAndPrecautions": "desvenlafaxine extended-release tablets available follows : ndc 68180-592-06 , bottle 30 tablets unit-of-use package 100 mg , reddish-orange , biconvex , round shaped film-coated tablets , debossed `` lu `` one side `` s62 `` side . ndc 68788-8556-3 bottle 30 tablets ndc 68788-8556-6 bottle 60 tablets ndc 68788-8556-9 bottle 90 tablets ndc 68788-8556-1 bottle 100 tablets store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . tablet contains 38 mg , 76 mg 152 mg desvenlafaxine succinate monohydrate equivalent 25 mg , 50 mg 100 mg desvenlafaxine , respectively .",
    "adverseReactions": "\u2022hypersensitivity desvenlafaxine succinate , venlafaxine hydrochloride excipients desvenlafaxine formulation . angioedema reported patients treated desvenlafaxine [ ( 6.1 ) ] . \u2022the maois intended treat psychiatric disorders desvenlafaxine within 7 days stopping treatment desvenlafaxine contraindicated increased risk serotonin syndrome . desvenlafaxine within 14 days stopping maoi intended treat psychiatric disorders also contraindicated [ ( 2.7 ) ( 5.2 ) ] . \u2022starting desvenlafaxine patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome [ ( 2.8 ) ( 5.2 ) ] .",
    "indications_original": "Desvenlafaxine extended-release tablet is indicated for the treatment of adults with major depressive disorder (MDD) [see CLINICAL STUDIES (14)].",
    "contraindications_original": "\u2022 Recommended dose: 50 mg once daily with or without food ( 2.1 ). \u2022 There was no evidence that doses greater than 50 mg per day confer any additional benefit ( 2.1 ). \u2022 The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment or dosing in severe renal and end-stage renal disease patients ( 2.1 ). \u2022 Discontinuation: Reduce dose gradually whenever possible ( 2.1 ). \u2022 Take tablets whole; do not divide, crush, chew, or dissolve ( 2.1 ). \u2022 Moderate renal impairment: Maximum dose 50 mg per day ( 2.2 ). \u2022 Severe renal impairment and end-stage renal disease: Maximum dose 25 mg per day or 50 mg every other day ( 2.2 ). \u2022 Moderate to severe hepatic impairment: Maximum dose 100 mg per day ( 2.3 ).",
    "warningsAndPrecautions_original": "Desvenlafaxine extended-release tablets are available as follows:\n                  NDC 68180-592-06, bottle of 30 tablets in unit-of-use package\n                  \n                     100 mg, reddish-orange, biconvex, round shaped film-coated tablets, debossed with \"LU\" on one side and \"S62\" on the other side.\n                  \n                  NDC 68788-8556-3 bottle of 30 tablets \n                  NDC 68788-8556-6 bottle of 60 tablets \n                  NDC 68788-8556-9 bottle of 90 tablets \n                  NDC 68788-8556-1 bottle of 100 tablets \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].\n                  Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine succinate monohydrate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine, respectively.",
    "adverseReactions_original": "\u2022Hypersensitivity to desvenlafaxine succinate,      venlafaxine hydrochloride or to any excipients in the desvenlafaxine formulation.      Angioedema has been reported in patients treated with desvenlafaxine [see      ADVERSE REACTIONS (6.1)].\n                     \n                     \n                        \u2022The use of MAOIs intended to treat psychiatric      disorders with desvenlafaxine or within 7 days of stopping treatment with desvenlafaxine      is contraindicated because of an increased risk of serotonin syndrome. The      use of desvenlafaxine within 14 days of stopping an MAOI intended to treat      psychiatric disorders is also contraindicated [see DOSAGE AND      ADMINISTRATION (2.7) and WARNINGS AND      PRECAUTIONS (5.2)].\n                     \n                     \n                        \u2022Starting desvenlafaxine in a patient who is being      treated with MAOIs such as linezolid or intravenous methylene blue is also      contraindicated because of an increased risk of serotonin syndrome [see      DOSAGE AND ADMINISTRATION (2.8) and WARNINGS      AND PRECAUTIONS (5.2)]."
}